No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
473681 |
1. Apply sex-specific ruleNone |
473681 |
2. Check conditionsNone |
473681 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
490 |
4. Check minimum number of eventsNone |
490 |
5. Include endpointsNone |
490 |
6. Filter based on genotype QC (FinnGen only) |
474 |
Control definitions (FinnGen only)
Control exclude
L12_URTICARIAERYTHEMA
Extra metadata
Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Similar endpoints
↥List of similar endpoints to
Universal erythroderma, KELA reimbursement
based on the number of shared cases.
Similar with more cases:
- Atopic dermatitis, strict definition with reimbursement
- Urticaria and erythema
- Diseases of the skin and subcutaneous tissue
- Any reimbursement code in KELA
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 3118 | 1019 | 2077 |
| Only index persons | 2650 | 908 | 1742 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.05 | 0.03 | 0.06 |
| Only index persons | 0.06 | 0.03 | 0.07 |
| Median age at first event (years) | |||
| Whole population | 50.11 | 51.31 | 49.42 |
| Only index persons | 48.21 | 49.83 | 47.37 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 474 | 170 | 304 |
| Unadjusted period prevalence (%) | 0.12 | 0.07 | 0.15 |
| Median age at first event (years) | 47.94 | 48.24 | 47.77 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
Mortality – FinRegistry
↥Association
Association between endpoint L12_ERYTHRO_KELA and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_ERYTHRO_KELA | 1.756 [1.38, 2.24] | < 0.001 |
| Birth year | 0.994 [0.99, 1.0] | 0.201 |
During the follow-up period (1.1.1998 — 31.12.2019), 107 out of 680 females with L12_ERYTHRO_KELA died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_ERYTHRO_KELA | 1.919 [1.61, 2.28] | < 0.001 |
| Birth year | 0.991 [0.98, 1.0] | 0.062 |
During the follow-up period (1.1.1998 — 31.12.2019), 254 out of 1333 males with L12_ERYTHRO_KELA died.
Mortality risk
Mortality risk for people of age
years, who have L12_ERYTHRO_KELA.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.161% | 0.426% |
| 5 | 0.981% | 2.332% |
| 10 | 2.483% | 6.368% |
| 15 | 4.943% | 11.795% |
| 20 | 8.337% | 19.381% |
Relationships between endpoints
↥Index endpoint: L12_ERYTHRO_KELA – Universal erythroderma, KELA reimbursement
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
Extremity
rg [CI]
Extremity
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data